Orthofix Medical Inc. (OFIX)
NASDAQ: OFIXHealth CareMedical/Dental InstrumentsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
OFIX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $247.41M
- Forward P/E
- 33.72
- EPS (TTM)
- -$1.10
- Dividend yield
- None
- 52-week range
- 6.04 – 16.42
- Day range
- 6.04 – 6.52
- Volume / Avg
- 451.03K / 481.16K
- Beta
- —
- Shares outstanding
- 40.76M
52-week range
OFIX stock today
Orthofix Medical (OFIX) closed at $6.07 on Nov 20, down 4.26% (-$0.27), versus the S&P 500's 3.70% decline. At this level, OFIX sits near the bottom of its 52-week range of $6.04 to $16.42: 63.0% below the high, set on Jan 8, 2026 and 0.6% above the low. OFIX is down 60.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 60.2%.
Orthofix Medical has posted a net loss over the last twelve months (EPS of -$1.10), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Orthofix Medical
Company profileOrthofix Medical Inc., together with its subsidiaries, operates as a medical technology company in the United States, Italy, the United Kingdom, France, Germany, Brazil, and internationally. It operates through two segments, Global Spine and Global Limb Reconstruction. The Global Spine segment manufactures, distributes, and provides support services for bone growth stimulation devices that enhance bone fusion; designs, develops, and markets a portfolio of spine fixation implant products for use throughout the spinal column; and offers bone graft substitutes, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers in various forms with supporting graft delivery solutions to treat various spinal, orthopedic, and dental conditions.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- CEO
- Mr. Massimo Calafiore
- Headquarters
- Lewisville, TX
- Employees
- 1,605
- IPO year
- 1992
- Website
- orthofix.com
Financial highlights
Full financialsIn fiscal 2025, Orthofix Medical generated $822.3 million in revenue, up 2.9% from fiscal 2024, its 3rd consecutive year of revenue growth. Orthofix Medical reported a net loss of $92.2 million, compared with a loss of $126.0 million a year earlier. Gross margin was 68.8% (up from 68.3%) and operating margin -9.9%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $822.31M | $799.49M | $746.64M | $460.71M | $464.48M |
| Growth | +2.85% | +7.08% | +62.06% | -0.81% | +14.25% |
| Net income | $-92.19M | $-126.00M | $-151.40M | $-19.75M | $-38.38M |
| EPS (diluted) | $-2.33 | $-3.30 | $-4.12 | $-0.98 | $-1.95 |
Analyst forecast
ForecastConsensus (4 analysts)
buy
Avg. price target
$10.00+64.74%
- Strong buy 1
- Buy 2
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 9, 2026
- EPS actual vs est.
- $-0.57 vs $-0.31
- Surprise
- -83.87%
OFIX news
All OFIX news- Orthofix Medical Inc. Reports Third Quarter 2026 Results and Revises Full-Year 2026 GuidanceNasdaq
- Orthofix Medical (OFIX) Q3 2026 Earnings Call TranscriptNasdaq
- Orthofix Medical Inc. Q3 Loss DeclinesNasdaq
- Orthofix Reports Third Quarter 2026 Results and Revises Full-Year 2026 GuidanceBusiness Wire
- Orthofix to Report Third Quarter 2026 Financial ResultsBusiness Wire
- SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of Orthofix Medical Inc. (NASDAQ: OFIX)PR Newswire
- SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of Orthofix Medical Inc. (NASDAQ: OFIX)PR Newswire
Orthofix Medical peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| SSIISS Innovations International Inc. | 1.27 | -0.78% | $254.86M | vs OFIX |
| OSUROraSure Technologies Inc. | 3.46 | -4.16% | $238.90M | vs OFIX |
| PROFProfound Medical Corp. | 6.38 | -3.19% | $233.68M | vs OFIX |
| CLPTClearPoint Neuro Inc. | 6.91 | -5.47% | $221.49M | vs OFIX |
| NPCENeuropace Inc. | 7.95 | -2.33% | $273.89M | vs OFIX |
| TMCITreace Medical Concepts Inc. | 4.31 | -0.92% | $282.56M | vs OFIX |
| INFUInfuSystems Holdings Inc. | 14.35 | +2.06% | $287.48M | vs OFIX |
| KTWOK2 Capital Acquisition Corporation Class A | 10.13 | 0.00% | $203.02M | vs OFIX |
Indexes, lists and sector
Orthofix Medical stock FAQ
What is Orthofix Medical's stock price today?
OFIX last traded at $6.07 as of Nov 20, 4:00 PM EST, down 4.26% on the day. Prices are delayed at least 15 minutes.
Who is Orthofix Medical's CEO?
Mr. Massimo Calafiore is the chief executive officer of Orthofix Medical Inc., which has about 1,605 employees.
What is the OFIX 52-week high?
The 52-week high for OFIX is $16.42 and the 52-week low is $6.04. The stock is currently 63.0% below its high.